http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Fri, 05 Jun 2026 20:11:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Sarepta+Therapeutics%2C+++++For%3A+Jun+04++Filed+by%3A+Boor+Kathryn+Jean/26612680.html si-local-file:///var/storage/secattach/20260605/26612680.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Sarepta+Therapeutics%2C+++++For%3A+Jun+04++Filed+by%3A+Boor+Kathryn+Jean/26612680.html Fri, 05 Jun 2026 20:11:00 -0400 O.00070249 SRPT http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Sarepta+Therapeutics%2C+++++For%3A+Jun+04++Filed+by%3A+Boor+Kathryn+Jean/26612680.html si-local-file:///var/storage/secattach/20260605/26612680.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Sarepta+Therapeutics%2C+++++For%3A+Jun+04++Filed+by%3A+Boor+Kathryn+Jean/26612680.html Fri, 05 Jun 2026 20:11:00 -0400 O.00070249 SRPT http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Sarepta+Therapeutics%2C+++++For%3A+Jun+04++Filed+by%3A+Mayo+Stephen/26612677.html si-local-file:///var/storage/secattach/20260605/26612677.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Sarepta+Therapeutics%2C+++++For%3A+Jun+04++Filed+by%3A+Mayo+Stephen/26612677.html Fri, 05 Jun 2026 20:10:00 -0400 O.00070249 SRPT http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Sarepta+Therapeutics%2C+++++For%3A+Jun+04++Filed+by%3A+Mayo+Stephen/26612677.html si-local-file:///var/storage/secattach/20260605/26612677.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Sarepta+Therapeutics%2C+++++For%3A+Jun+04++Filed+by%3A+Mayo+Stephen/26612677.html Fri, 05 Jun 2026 20:10:00 -0400 O.00070249 SRPT http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Sarepta+Therapeutics%2C+++++For%3A+Jun+04++Filed+by%3A+Wigzell+Hans+Lennart+Rudolf/26612675.html si-local-file:///var/storage/secattach/20260605/26612675.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Sarepta+Therapeutics%2C+++++For%3A+Jun+04++Filed+by%3A+Wigzell+Hans+Lennart+Rudolf/26612675.html Fri, 05 Jun 2026 20:09:00 -0400 O.00070249 SRPT http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Sarepta+Therapeutics%2C+++++For%3A+Jun+04++Filed+by%3A+Wigzell+Hans+Lennart+Rudolf/26612675.html si-local-file:///var/storage/secattach/20260605/26612675.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Sarepta+Therapeutics%2C+++++For%3A+Jun+04++Filed+by%3A+Wigzell+Hans+Lennart+Rudolf/26612675.html Fri, 05 Jun 2026 20:09:00 -0400 O.00070249 SRPT http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Sarepta+Therapeutics%2C+++++For%3A+Jun+04++Filed+by%3A+BEHRENS+M+KATHLEEN/26612671.html si-local-file:///var/storage/secattach/20260605/26612671.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Sarepta+Therapeutics%2C+++++For%3A+Jun+04++Filed+by%3A+BEHRENS+M+KATHLEEN/26612671.html Fri, 05 Jun 2026 20:08:00 -0400 O.00070249 SRPT http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Sarepta+Therapeutics%2C+++++For%3A+Jun+04++Filed+by%3A+BEHRENS+M+KATHLEEN/26612671.html si-local-file:///var/storage/secattach/20260605/26612671.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Sarepta+Therapeutics%2C+++++For%3A+Jun+04++Filed+by%3A+BEHRENS+M+KATHLEEN/26612671.html Fri, 05 Jun 2026 20:08:00 -0400 O.00070249 SRPT http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Sarepta+Therapeutics%2C+++++For%3A+Jun+04++Filed+by%3A+Connelly+Deirdre+P/26612670.html si-local-file:///var/storage/secattach/20260605/26612670.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Sarepta+Therapeutics%2C+++++For%3A+Jun+04++Filed+by%3A+Connelly+Deirdre+P/26612670.html Fri, 05 Jun 2026 20:07:00 -0400 O.00070249 SRPT http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Sarepta+Therapeutics%2C+++++For%3A+Jun+04++Filed+by%3A+Connelly+Deirdre+P/26612670.html si-local-file:///var/storage/secattach/20260605/26612670.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Sarepta+Therapeutics%2C+++++For%3A+Jun+04++Filed+by%3A+Connelly+Deirdre+P/26612670.html Fri, 05 Jun 2026 20:07:00 -0400 O.00070249 SRPT http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Sarepta+Therapeutics%2C+++++For%3A+Jun+04++Filed+by%3A+Nicaise+Claude/26612666.html si-local-file:///var/storage/secattach/20260605/26612666.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Sarepta+Therapeutics%2C+++++For%3A+Jun+04++Filed+by%3A+Nicaise+Claude/26612666.html Fri, 05 Jun 2026 20:04:00 -0400 O.00070249 SRPT http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Sarepta+Therapeutics%2C+++++For%3A+Jun+04++Filed+by%3A+Nicaise+Claude/26612666.html si-local-file:///var/storage/secattach/20260605/26612666.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Sarepta+Therapeutics%2C+++++For%3A+Jun+04++Filed+by%3A+Nicaise+Claude/26612666.html Fri, 05 Jun 2026 20:04:00 -0400 O.00070249 SRPT http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Sarepta+Therapeutics%2C+++++For%3A+Jun+04++Filed+by%3A+Barry+Richard/26612664.html si-local-file:///var/storage/secattach/20260605/26612664.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Sarepta+Therapeutics%2C+++++For%3A+Jun+04++Filed+by%3A+Barry+Richard/26612664.html Fri, 05 Jun 2026 20:02:00 -0400 O.00070249 SRPT http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Sarepta+Therapeutics%2C+++++For%3A+Jun+04++Filed+by%3A+Barry+Richard/26612664.html si-local-file:///var/storage/secattach/20260605/26612664.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Sarepta+Therapeutics%2C+++++For%3A+Jun+04++Filed+by%3A+Barry+Richard/26612664.html Fri, 05 Jun 2026 20:02:00 -0400 O.00070249 SRPT http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Sarepta+Therapeutics%2C+++++For%3A+Jun+04++Filed+by%3A+Chambers+Michael+Andrew/26612665.html si-local-file:///var/storage/secattach/20260605/26612665.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Sarepta+Therapeutics%2C+++++For%3A+Jun+04++Filed+by%3A+Chambers+Michael+Andrew/26612665.html Fri, 05 Jun 2026 20:02:00 -0400 O.00070249 SRPT http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Sarepta+Therapeutics%2C+++++For%3A+Jun+04++Filed+by%3A+Chambers+Michael+Andrew/26612665.html si-local-file:///var/storage/secattach/20260605/26612665.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Sarepta+Therapeutics%2C+++++For%3A+Jun+04++Filed+by%3A+Chambers+Michael+Andrew/26612665.html Fri, 05 Jun 2026 20:02:00 -0400 O.00070249 SRPT http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++Sarepta+Therapeutics%2C++++++++++++++++/26606541.html si-local-file:///var/storage/secattach/20260604/26606541.html http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++Sarepta+Therapeutics%2C++++++++++++++++/26606541.html Thu, 04 Jun 2026 16:56:00 -0400 O.00070249 SRPT http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++Sarepta+Therapeutics%2C++++++++++++++++/26606541.html si-local-file:///var/storage/secattach/20260604/26606541.html http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++Sarepta+Therapeutics%2C++++++++++++++++/26606541.html Thu, 04 Jun 2026 16:56:00 -0400 O.00070249 SRPT http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Sarepta+Therapeutics%2C+++++For%3A+Jun+04/26606163.html si-local-file:///var/storage/secattach/20260604/26606163.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Sarepta+Therapeutics%2C+++++For%3A+Jun+04/26606163.html Thu, 04 Jun 2026 16:30:00 -0400 O.00070249 SRPT http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Sarepta+Therapeutics%2C+++++For%3A+Jun+04/26606163.html si-local-file:///var/storage/secattach/20260604/26606163.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Sarepta+Therapeutics%2C+++++For%3A+Jun+04/26606163.html Thu, 04 Jun 2026 16:30:00 -0400 O.00070249 SRPT http://www.streetinsider.com/Press+Releases/Platform+Biotech+Models+Draw+Investor+Eyes+as+Drug-Delivery+Markets+Head+Toward+%24410+Billion/26595903.html <p>AUSTIN, Texas, June 03, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=YACQHg4PypDB2_ntAGnkX8xPzHpTEk3itUBM6rUMdg6qhiIGG14V-nrpF7iOWpufVnBZUuOEBoSEK8zv8IMX-aFxdncbvJFLnIwXJ_b6lNxSGlkLoACuu05ew9bHE4JTppN5h18mKHYGUasXJZqtaKKfU_7r3CMfnhpes6t-xlxrO5uXcdkx2lmtBUQUpmEaFfVKSJiHYngrtdwsUTSpFcWw5Q4nmlUtC7FH04Fdh7bWT3B3E9sFZyjhg-rXK9e6eyb2wUHekiIVoL-82WWXslssNnJiUYrO_-EjO5vRyDzOFPXnABzoPmiqIK-ounSo" rel="nofollow" target="_blank">BioMedWire Editorial Coverage</a>: With oncology drug-development expenses continuing to rise and regulatory approvals becoming harder to secure, biotechnology companies are placing greater emphasis on extracting more value from existing therapies through cutting-edge delivery technologies rather than betting solely on the discovery of wholly new compounds. Across the life sciences industry, mounting interest is being directed toward nanoparticle-based platforms, intravenous reformulation strategies and precise pharmacokinetic engineering designed to potentially strengthen bioavailability, systemic exposure, tolerability and dosing reliability of established cancer medicines. Within this broader movement, Oncotelic Therapeutics Inc. http://www.streetinsider.com/Press+Releases/Platform+Biotech+Models+Draw+Investor+Eyes+as+Drug-Delivery+Markets+Head+Toward+%24410+Billion/26595903.html Wed, 03 Jun 2026 08:30:00 -0400 MRNA MRNA RVMD RVMD SRPT SRPT http://www.streetinsider.com/Press+Releases/Platform+Biotech+Models+Draw+Investor+Eyes+as+Drug-Delivery+Markets+Head+Toward+%24410+Billion/26595903.html <p>AUSTIN, Texas, June 03, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=YACQHg4PypDB2_ntAGnkX8xPzHpTEk3itUBM6rUMdg6qhiIGG14V-nrpF7iOWpufVnBZUuOEBoSEK8zv8IMX-aFxdncbvJFLnIwXJ_b6lNxSGlkLoACuu05ew9bHE4JTppN5h18mKHYGUasXJZqtaKKfU_7r3CMfnhpes6t-xlxrO5uXcdkx2lmtBUQUpmEaFfVKSJiHYngrtdwsUTSpFcWw5Q4nmlUtC7FH04Fdh7bWT3B3E9sFZyjhg-rXK9e6eyb2wUHekiIVoL-82WWXslssNnJiUYrO_-EjO5vRyDzOFPXnABzoPmiqIK-ounSo" rel="nofollow" target="_blank">BioMedWire Editorial Coverage</a>: With oncology drug-development expenses continuing to rise and regulatory approvals becoming harder to secure, biotechnology companies are placing greater emphasis on extracting more value from existing therapies through cutting-edge delivery technologies rather than betting solely on the discovery of wholly new compounds. Across the life sciences industry, mounting interest is being directed toward nanoparticle-based platforms, intravenous reformulation strategies and precise pharmacokinetic engineering designed to potentially strengthen bioavailability, systemic exposure, tolerability and dosing reliability of established cancer medicines. Within this broader movement, Oncotelic Therapeutics Inc. http://www.streetinsider.com/Press+Releases/Platform+Biotech+Models+Draw+Investor+Eyes+as+Drug-Delivery+Markets+Head+Toward+%24410+Billion/26595903.html Wed, 03 Jun 2026 08:30:00 -0400 MRNA MRNA RVMD RVMD SRPT SRPT http://www.streetinsider.com/Press+Releases/Platform+Biotech+Models+Draw+Investor+Eyes+as+Drug-Delivery+Markets+Head+Toward+%24410+Billion/26595903.html <p>AUSTIN, Texas, June 03, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=YACQHg4PypDB2_ntAGnkX8xPzHpTEk3itUBM6rUMdg6qhiIGG14V-nrpF7iOWpufVnBZUuOEBoSEK8zv8IMX-aFxdncbvJFLnIwXJ_b6lNxSGlkLoACuu05ew9bHE4JTppN5h18mKHYGUasXJZqtaKKfU_7r3CMfnhpes6t-xlxrO5uXcdkx2lmtBUQUpmEaFfVKSJiHYngrtdwsUTSpFcWw5Q4nmlUtC7FH04Fdh7bWT3B3E9sFZyjhg-rXK9e6eyb2wUHekiIVoL-82WWXslssNnJiUYrO_-EjO5vRyDzOFPXnABzoPmiqIK-ounSo" rel="nofollow" target="_blank">BioMedWire Editorial Coverage</a>: With oncology drug-development expenses continuing to rise and regulatory approvals becoming harder to secure, biotechnology companies are placing greater emphasis on extracting more value from existing therapies through cutting-edge delivery technologies rather than betting solely on the discovery of wholly new compounds. Across the life sciences industry, mounting interest is being directed toward nanoparticle-based platforms, intravenous reformulation strategies and precise pharmacokinetic engineering designed to potentially strengthen bioavailability, systemic exposure, tolerability and dosing reliability of established cancer medicines. Within this broader movement, Oncotelic Therapeutics Inc. http://www.streetinsider.com/Press+Releases/Platform+Biotech+Models+Draw+Investor+Eyes+as+Drug-Delivery+Markets+Head+Toward+%24410+Billion/26595903.html Wed, 03 Jun 2026 08:30:00 -0400 MRNA MRNA RVMD RVMD SRPT SRPT http://www.streetinsider.com/Press+Releases/Platform+Biotech+Models+Draw+Investor+Eyes+as+Drug-Delivery+Markets+Head+Toward+%24410+Billion/26595903.html <p>AUSTIN, Texas, June 03, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=YACQHg4PypDB2_ntAGnkX8xPzHpTEk3itUBM6rUMdg6qhiIGG14V-nrpF7iOWpufVnBZUuOEBoSEK8zv8IMX-aFxdncbvJFLnIwXJ_b6lNxSGlkLoACuu05ew9bHE4JTppN5h18mKHYGUasXJZqtaKKfU_7r3CMfnhpes6t-xlxrO5uXcdkx2lmtBUQUpmEaFfVKSJiHYngrtdwsUTSpFcWw5Q4nmlUtC7FH04Fdh7bWT3B3E9sFZyjhg-rXK9e6eyb2wUHekiIVoL-82WWXslssNnJiUYrO_-EjO5vRyDzOFPXnABzoPmiqIK-ounSo" rel="nofollow" target="_blank">BioMedWire Editorial Coverage</a>: With oncology drug-development expenses continuing to rise and regulatory approvals becoming harder to secure, biotechnology companies are placing greater emphasis on extracting more value from existing therapies through cutting-edge delivery technologies rather than betting solely on the discovery of wholly new compounds. Across the life sciences industry, mounting interest is being directed toward nanoparticle-based platforms, intravenous reformulation strategies and precise pharmacokinetic engineering designed to potentially strengthen bioavailability, systemic exposure, tolerability and dosing reliability of established cancer medicines. Within this broader movement, Oncotelic Therapeutics Inc. http://www.streetinsider.com/Press+Releases/Platform+Biotech+Models+Draw+Investor+Eyes+as+Drug-Delivery+Markets+Head+Toward+%24410+Billion/26595903.html Wed, 03 Jun 2026 08:30:00 -0400 MRNA MRNA RVMD RVMD SRPT SRPT http://www.streetinsider.com/Press+Releases/Platform+Biotech+Models+Draw+Investor+Eyes+as+Drug-Delivery+Markets+Head+Toward+%24410+Billion/26595903.html <p>AUSTIN, Texas, June 03, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=YACQHg4PypDB2_ntAGnkX8xPzHpTEk3itUBM6rUMdg6qhiIGG14V-nrpF7iOWpufVnBZUuOEBoSEK8zv8IMX-aFxdncbvJFLnIwXJ_b6lNxSGlkLoACuu05ew9bHE4JTppN5h18mKHYGUasXJZqtaKKfU_7r3CMfnhpes6t-xlxrO5uXcdkx2lmtBUQUpmEaFfVKSJiHYngrtdwsUTSpFcWw5Q4nmlUtC7FH04Fdh7bWT3B3E9sFZyjhg-rXK9e6eyb2wUHekiIVoL-82WWXslssNnJiUYrO_-EjO5vRyDzOFPXnABzoPmiqIK-ounSo" rel="nofollow" target="_blank">BioMedWire Editorial Coverage</a>: With oncology drug-development expenses continuing to rise and regulatory approvals becoming harder to secure, biotechnology companies are placing greater emphasis on extracting more value from existing therapies through cutting-edge delivery technologies rather than betting solely on the discovery of wholly new compounds. Across the life sciences industry, mounting interest is being directed toward nanoparticle-based platforms, intravenous reformulation strategies and precise pharmacokinetic engineering designed to potentially strengthen bioavailability, systemic exposure, tolerability and dosing reliability of established cancer medicines. Within this broader movement, Oncotelic Therapeutics Inc. http://www.streetinsider.com/Press+Releases/Platform+Biotech+Models+Draw+Investor+Eyes+as+Drug-Delivery+Markets+Head+Toward+%24410+Billion/26595903.html Wed, 03 Jun 2026 08:30:00 -0400 MRNA MRNA RVMD RVMD SRPT SRPT